Mounjaro 2.5 mg Pen

Mounjaro 2.5 mg Pen

Description:

Mounjaro 2.5 mg pen (mounjaro 2.5 mg/0.5 ml solution for injection) is a prescription injectable medicine containing tirzepatide, a dual GIP and GLP-1 receptor agonist. It is used for the management of type 2 diabetes mellitus and for medical weight management in adults, as an adjunct to diet and exercise. This pre-filled subcutaneous pen is designed for once-weekly self-injection to help improve blood glucose control and support clinically significant weight loss under medical supervision.

Indications:

• Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
• • As monotherapy when metformin is considered inappropriate due to intolerance or contraindications.
• • In combination with other medicinal products for the treatment of diabetes (e.g. metformin, SGLT2 inhibitors, insulin) as prescribed by a healthcare professional.
• Weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with:
• • Body mass index (BMI) >= 30 kg/m2 (obesity), or
• • BMI >= 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition such as hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus.
• Helps reduce elevated blood glucose (hyperglycaemia) and improve overall glycaemic control (fasting and postprandial glucose) in adults with type 2 diabetes.

Active Ingredients / Key Components:

• Tirzepatide – 2.5 mg per 0.5 ml pre-filled pen (5 mg/ml).
• Excipients: Full excipient list is not provided in the available information (For full ingredient information, please check the product leaflet or the manufacturer’s official website.). Typical excipients may include buffers, stabilisers, and water for injections; exact composition is not available.

Dosage & Administration / How to Use:

• Starting dose: 2.5 mg tirzepatide once weekly.
• The 2.5 mg dose is a starting dose used for treatment initiation and is not intended as the long-term maintenance dose.
• Titration: After 4 weeks on 2.5 mg once weekly, the dose should be increased to 5 mg once weekly.
• If additional glycaemic or weight control is needed, the dose may be increased in 2.5 mg increments (e.g. 7.5 mg, 10 mg, 12.5 mg, 15 mg) after a minimum of 4 weeks on the current dose, according to your doctor’s instructions.
• Recommended maintenance doses: 5 mg, 10 mg, or 15 mg once weekly, as determined by the treating physician.
• Maximum dose: 15 mg once weekly.
• Route of administration: Subcutaneous injection only. Do not inject intravenously or intramuscularly.
• Injection sites: Abdomen, thigh, or upper arm. Rotate injection sites with each dose to reduce the risk of local irritation.
• The dose can be administered at any time of the day, with or without meals, on the same day each week.
• If you also use insulin, inject mounjaro and insulin in separate injection sites; do not mix them in the same syringe.
• Missed dose: If a dose is missed, follow your doctor’s or the official patient leaflet instructions. Do not take a double dose to make up for a forgotten dose.
• Use exactly as prescribed by your healthcare provider. Do not change your dose or stop treatment without medical advice.

Clinical Benefits:

• Improves glycaemic control in adults with type 2 diabetes by enhancing glucose-dependent insulin secretion and reducing elevated blood sugar levels.
• Promotes clinically meaningful weight loss and supports long-term weight maintenance when combined with a reduced-calorie diet and increased physical activity.
• Reduces appetite and food intake through dual GIP and GLP-1 receptor agonism, helping patients adhere to lifestyle changes.
• May improve cardiometabolic risk factors associated with obesity and type 2 diabetes, such as high blood pressure, dyslipidaemia, and central adiposity (based on class effects and clinical data with tirzepatide).
• Once-weekly dosing with a pre-filled pen supports convenient, consistent use and may improve treatment adherence compared to daily injections.

Warnings & Contraindications:

• For adults with type 2 diabetes or indicated weight management only. Not for use in type 1 diabetes or for the treatment of diabetic ketoacidosis.
• Do not use if you are allergic (hypersensitive) to tirzepatide or any of the excipients in the product.
• Use with caution in patients with a history of pancreatitis; inform your doctor immediately if you experience severe, persistent abdominal pain, with or without vomiting.
• Use with caution in patients with severe gastrointestinal disease, including severe gastroparesis, as GLP-1/GIP agonists slow gastric emptying.
• Risk of hypoglycaemia is increased when used in combination with insulin or sulfonylureas; your doctor may need to adjust the dose of these medicines.
• Not recommended in patients with a personal or family history of certain types of thyroid cancer (e.g. medullary thyroid carcinoma) or multiple endocrine neoplasia syndrome type 2 (MEN 2), unless specifically assessed and approved by a specialist, in line with local product information.
• Inform your doctor if you have kidney or liver impairment, cardiovascular disease, or are taking other glucose-lowering medicines.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. Weight-loss treatment is generally not recommended during pregnancy and breastfeeding.
• May cause dehydration due to gastrointestinal side effects (nausea, vomiting, diarrhoea); maintain adequate fluid intake.
• May affect the absorption of orally administered medicines by delaying gastric emptying; your doctor will advise if any adjustments are needed.
• Consult your doctor before use if you are taking other medications or have medical conditions such as pancreatitis, gallbladder disease, severe gastrointestinal disease, or thyroid disorders.
• Keep out of reach of children.
• This product is a prescription medicine and must be used under medical supervision.

Side Effects:

• Common side effects: Nausea, vomiting, diarrhoea, constipation, decreased appetite, abdominal pain, indigestion, belching, and injection site reactions (redness, itching, or swelling).
• Metabolic effects: Hypoglycaemia (low blood sugar) especially when used with insulin or sulfonylureas; symptoms include sweating, shakiness, dizziness, fast heartbeat, hunger, or confusion.
• Less common but serious side effects: Acute pancreatitis (severe and persistent abdominal pain, possibly radiating to the back, with or without vomiting), gallbladder disease (e.g. cholelithiasis, cholecystitis), severe allergic reactions (rash, swelling of face or throat, difficulty breathing).
• If you experience signs of severe abdominal pain, persistent vomiting, symptoms of an allergic reaction, or signs of very low blood sugar that do not improve with treatment, seek immediate medical attention.
• Not all possible side effects are listed. Always refer to the official patient leaflet and consult your healthcare provider if you notice any unusual symptoms.

Storage Instructions:

Store in a refrigerator at 2–8 °c, protected from light. Do not freeze. If the pen has been frozen, it must not be used. Keep the pen in the original carton until time of use to protect from light. After removal from the refrigerator, follow the storage duration and temperature limits stated in the official product leaflet (information not fully available here). Keep out of reach of children.

Specifications:

• Product type: Prescription medicine – injectable solution for subcutaneous use.
• Active ingredient strength: tirzepatide 2.5 mg per 0.5 ml pre-filled pen (5 mg/ml).
• Form: Pre-filled subcutaneous injection pen.
• Pack information: Commonly supplied as a pack of multiple pens (e.g. 4 pens) for once-weekly dosing; exact pack size may vary by market and is not fully specified in the available information (For full ingredient information, please check the product leaflet or the manufacturer’s official website.).
• Intended users: Adults with type 2 diabetes and/or obesity/overweight meeting indication criteria, under medical supervision.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.